Diagnostic Performance of miR-485-3p in Patients with Parkinson’s Disease and its Relationship with Neuroinflammation
Parkinson’s disease (PD) is one of the most common progressive neurodegenerative diseases. Some microRNAs (miRNAs) play critical roles in the development of many neurological diseases. This study aims to evaluate the clinical significance and biological function of miR-485-3p in the development and...
Gespeichert in:
| Veröffentlicht in: | Neuromolecular medicine 2022-06, Vol.24 (2), p.195-201 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 201 |
|---|---|
| container_issue | 2 |
| container_start_page | 195 |
| container_title | Neuromolecular medicine |
| container_volume | 24 |
| creator | Lin, Xia Wang, Rui Li, Ran Tao, Taotao Zhang, Danhong Qi, Yuxiang |
| description | Parkinson’s disease (PD) is one of the most common progressive neurodegenerative diseases. Some microRNAs (miRNAs) play critical roles in the development of many neurological diseases. This study aims to evaluate the clinical significance and biological function of miR-485-3p in the development and progression of PD. The expression of miR-485-3p in serum of PD patients was analyzed by quantitative real-time PCR (qRT-PCR). LPS-treated microglia BV2 cells were used to mimic neuroinflammation in the pathogenesis of PD. The levels of inflammatory cytokines, including IL-1β, IL-6 and TNF-α, were detected by enzyme-linked immunosorbent assay (ELISA). The diagnosis value of miR-485-3p was evaluated by plotting receiver operating characteristic (ROC) curves. A luciferase reporter assay was performed to demonstrate the interaction between miR-485-3p and FBXO45. The results showed that miR-485-3p was significantly up-regulated in serum of PD patients compared with that in both Alzheimer’s disease (AD) and healthy cases, and had diagnostic accuracy for PD screening. The activated microglia BV2 cells induced by LPS also had elevated miR-485-3p, and the knockdown of miR-485-3p inhibited the release of pro-inflammatory cytokines. FBXO protein 45 (FBXO45) served as a potential target of miR-485-3p, which was speculated to mediate the function of miR-485-3p. Our results suggest that the up-regulated expression of miR-485-3p in PD may be a novel diagnostic biomarker for PD. Reducing the expression level of miR-485-3p can inhibit the inflammatory responses of BV2 cells, which indicated that miR-485-3p, as a regulator of neuroinflammation, may have the potential as a therapeutic target in PD. |
| doi_str_mv | 10.1007/s12017-021-08676-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2553232720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2666132698</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-14fe529e29526cbf90bf8fcf1638d6c50425d3356ffb62cad8dd2846238d695f3</originalsourceid><addsrcrecordid>eNp9kc1OHSEYholpo1Z7Ay4akm7c0MLHwDDLRu1PYlpj7JpwGFDsDJzCTE7c9Ta8Pa-kHEfbpIuugLzP934kD0JHjL5jlLbvCwPKWkKBEapkK8lmB-0zITrCWNu82N65IIyqZg-9KuWWUgDG2C7a4w20XavUPtqcBnMdU5mCxRcu-5RHE63DyeMxXJJGCcLXOER8Yabg4lTwJkw39ZV_hFhSfPh1X_BpKM4Uh03scajIpRsqnWK5CeuF_-rmnEL0gxnHx-gQvfRmKO7103mAvn88uzr5TM6_ffpy8uGcWN6KibDGOwGdg06AtCvf0ZVX3nomueqlFbQB0XMupPcrCdb0qu9BNRK2cSc8P0DHS-86p5-zK5MeQ7FuGEx0aS4ahODAoQVa0bf_oLdpzrH-ToOUknGQnaoULJTNqZTsvF7nMJp8pxnVWy160aKrFv2oRW_q0Jun6nk1uv7PyLOHCvAFKDWK1y7_3f2f2t8zS5nu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2666132698</pqid></control><display><type>article</type><title>Diagnostic Performance of miR-485-3p in Patients with Parkinson’s Disease and its Relationship with Neuroinflammation</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Lin, Xia ; Wang, Rui ; Li, Ran ; Tao, Taotao ; Zhang, Danhong ; Qi, Yuxiang</creator><creatorcontrib>Lin, Xia ; Wang, Rui ; Li, Ran ; Tao, Taotao ; Zhang, Danhong ; Qi, Yuxiang</creatorcontrib><description>Parkinson’s disease (PD) is one of the most common progressive neurodegenerative diseases. Some microRNAs (miRNAs) play critical roles in the development of many neurological diseases. This study aims to evaluate the clinical significance and biological function of miR-485-3p in the development and progression of PD. The expression of miR-485-3p in serum of PD patients was analyzed by quantitative real-time PCR (qRT-PCR). LPS-treated microglia BV2 cells were used to mimic neuroinflammation in the pathogenesis of PD. The levels of inflammatory cytokines, including IL-1β, IL-6 and TNF-α, were detected by enzyme-linked immunosorbent assay (ELISA). The diagnosis value of miR-485-3p was evaluated by plotting receiver operating characteristic (ROC) curves. A luciferase reporter assay was performed to demonstrate the interaction between miR-485-3p and FBXO45. The results showed that miR-485-3p was significantly up-regulated in serum of PD patients compared with that in both Alzheimer’s disease (AD) and healthy cases, and had diagnostic accuracy for PD screening. The activated microglia BV2 cells induced by LPS also had elevated miR-485-3p, and the knockdown of miR-485-3p inhibited the release of pro-inflammatory cytokines. FBXO protein 45 (FBXO45) served as a potential target of miR-485-3p, which was speculated to mediate the function of miR-485-3p. Our results suggest that the up-regulated expression of miR-485-3p in PD may be a novel diagnostic biomarker for PD. Reducing the expression level of miR-485-3p can inhibit the inflammatory responses of BV2 cells, which indicated that miR-485-3p, as a regulator of neuroinflammation, may have the potential as a therapeutic target in PD.</description><identifier>ISSN: 1535-1084</identifier><identifier>EISSN: 1559-1174</identifier><identifier>DOI: 10.1007/s12017-021-08676-w</identifier><identifier>PMID: 34279788</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Alzheimer's disease ; Biomedical and Life Sciences ; Biomedicine ; Clinical significance ; Cytokines ; Cytokines - metabolism ; Enzyme-linked immunosorbent assay ; F-Box Proteins ; Humans ; IL-1β ; Inflammation ; Interleukin 6 ; Internal Medicine ; Lipopolysaccharides ; Lipopolysaccharides - pharmacology ; Microglia ; MicroRNAs ; miRNA ; Movement disorders ; Neurodegenerative diseases ; Neuroinflammatory Diseases ; Neurological diseases ; Neurology ; Neurosciences ; Original Paper ; Parkinson Disease - metabolism ; Parkinson's disease ; Patients ; Therapeutic targets ; Tumor necrosis factor-α</subject><ispartof>Neuromolecular medicine, 2022-06, Vol.24 (2), p.195-201</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-14fe529e29526cbf90bf8fcf1638d6c50425d3356ffb62cad8dd2846238d695f3</citedby><cites>FETCH-LOGICAL-c375t-14fe529e29526cbf90bf8fcf1638d6c50425d3356ffb62cad8dd2846238d695f3</cites><orcidid>0000-0003-4648-6256</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12017-021-08676-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12017-021-08676-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34279788$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Xia</creatorcontrib><creatorcontrib>Wang, Rui</creatorcontrib><creatorcontrib>Li, Ran</creatorcontrib><creatorcontrib>Tao, Taotao</creatorcontrib><creatorcontrib>Zhang, Danhong</creatorcontrib><creatorcontrib>Qi, Yuxiang</creatorcontrib><title>Diagnostic Performance of miR-485-3p in Patients with Parkinson’s Disease and its Relationship with Neuroinflammation</title><title>Neuromolecular medicine</title><addtitle>Neuromol Med</addtitle><addtitle>Neuromolecular Med</addtitle><description>Parkinson’s disease (PD) is one of the most common progressive neurodegenerative diseases. Some microRNAs (miRNAs) play critical roles in the development of many neurological diseases. This study aims to evaluate the clinical significance and biological function of miR-485-3p in the development and progression of PD. The expression of miR-485-3p in serum of PD patients was analyzed by quantitative real-time PCR (qRT-PCR). LPS-treated microglia BV2 cells were used to mimic neuroinflammation in the pathogenesis of PD. The levels of inflammatory cytokines, including IL-1β, IL-6 and TNF-α, were detected by enzyme-linked immunosorbent assay (ELISA). The diagnosis value of miR-485-3p was evaluated by plotting receiver operating characteristic (ROC) curves. A luciferase reporter assay was performed to demonstrate the interaction between miR-485-3p and FBXO45. The results showed that miR-485-3p was significantly up-regulated in serum of PD patients compared with that in both Alzheimer’s disease (AD) and healthy cases, and had diagnostic accuracy for PD screening. The activated microglia BV2 cells induced by LPS also had elevated miR-485-3p, and the knockdown of miR-485-3p inhibited the release of pro-inflammatory cytokines. FBXO protein 45 (FBXO45) served as a potential target of miR-485-3p, which was speculated to mediate the function of miR-485-3p. Our results suggest that the up-regulated expression of miR-485-3p in PD may be a novel diagnostic biomarker for PD. Reducing the expression level of miR-485-3p can inhibit the inflammatory responses of BV2 cells, which indicated that miR-485-3p, as a regulator of neuroinflammation, may have the potential as a therapeutic target in PD.</description><subject>Alzheimer's disease</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Clinical significance</subject><subject>Cytokines</subject><subject>Cytokines - metabolism</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>F-Box Proteins</subject><subject>Humans</subject><subject>IL-1β</subject><subject>Inflammation</subject><subject>Interleukin 6</subject><subject>Internal Medicine</subject><subject>Lipopolysaccharides</subject><subject>Lipopolysaccharides - pharmacology</subject><subject>Microglia</subject><subject>MicroRNAs</subject><subject>miRNA</subject><subject>Movement disorders</subject><subject>Neurodegenerative diseases</subject><subject>Neuroinflammatory Diseases</subject><subject>Neurological diseases</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Original Paper</subject><subject>Parkinson Disease - metabolism</subject><subject>Parkinson's disease</subject><subject>Patients</subject><subject>Therapeutic targets</subject><subject>Tumor necrosis factor-α</subject><issn>1535-1084</issn><issn>1559-1174</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc1OHSEYholpo1Z7Ay4akm7c0MLHwDDLRu1PYlpj7JpwGFDsDJzCTE7c9Ta8Pa-kHEfbpIuugLzP934kD0JHjL5jlLbvCwPKWkKBEapkK8lmB-0zITrCWNu82N65IIyqZg-9KuWWUgDG2C7a4w20XavUPtqcBnMdU5mCxRcu-5RHE63DyeMxXJJGCcLXOER8Yabg4lTwJkw39ZV_hFhSfPh1X_BpKM4Uh03scajIpRsqnWK5CeuF_-rmnEL0gxnHx-gQvfRmKO7103mAvn88uzr5TM6_ffpy8uGcWN6KibDGOwGdg06AtCvf0ZVX3nomueqlFbQB0XMupPcrCdb0qu9BNRK2cSc8P0DHS-86p5-zK5MeQ7FuGEx0aS4ahODAoQVa0bf_oLdpzrH-ToOUknGQnaoULJTNqZTsvF7nMJp8pxnVWy160aKrFv2oRW_q0Jun6nk1uv7PyLOHCvAFKDWK1y7_3f2f2t8zS5nu</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>Lin, Xia</creator><creator>Wang, Rui</creator><creator>Li, Ran</creator><creator>Tao, Taotao</creator><creator>Zhang, Danhong</creator><creator>Qi, Yuxiang</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4648-6256</orcidid></search><sort><creationdate>20220601</creationdate><title>Diagnostic Performance of miR-485-3p in Patients with Parkinson’s Disease and its Relationship with Neuroinflammation</title><author>Lin, Xia ; Wang, Rui ; Li, Ran ; Tao, Taotao ; Zhang, Danhong ; Qi, Yuxiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-14fe529e29526cbf90bf8fcf1638d6c50425d3356ffb62cad8dd2846238d695f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Alzheimer's disease</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Clinical significance</topic><topic>Cytokines</topic><topic>Cytokines - metabolism</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>F-Box Proteins</topic><topic>Humans</topic><topic>IL-1β</topic><topic>Inflammation</topic><topic>Interleukin 6</topic><topic>Internal Medicine</topic><topic>Lipopolysaccharides</topic><topic>Lipopolysaccharides - pharmacology</topic><topic>Microglia</topic><topic>MicroRNAs</topic><topic>miRNA</topic><topic>Movement disorders</topic><topic>Neurodegenerative diseases</topic><topic>Neuroinflammatory Diseases</topic><topic>Neurological diseases</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Original Paper</topic><topic>Parkinson Disease - metabolism</topic><topic>Parkinson's disease</topic><topic>Patients</topic><topic>Therapeutic targets</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Xia</creatorcontrib><creatorcontrib>Wang, Rui</creatorcontrib><creatorcontrib>Li, Ran</creatorcontrib><creatorcontrib>Tao, Taotao</creatorcontrib><creatorcontrib>Zhang, Danhong</creatorcontrib><creatorcontrib>Qi, Yuxiang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Neuromolecular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Xia</au><au>Wang, Rui</au><au>Li, Ran</au><au>Tao, Taotao</au><au>Zhang, Danhong</au><au>Qi, Yuxiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic Performance of miR-485-3p in Patients with Parkinson’s Disease and its Relationship with Neuroinflammation</atitle><jtitle>Neuromolecular medicine</jtitle><stitle>Neuromol Med</stitle><addtitle>Neuromolecular Med</addtitle><date>2022-06-01</date><risdate>2022</risdate><volume>24</volume><issue>2</issue><spage>195</spage><epage>201</epage><pages>195-201</pages><issn>1535-1084</issn><eissn>1559-1174</eissn><abstract>Parkinson’s disease (PD) is one of the most common progressive neurodegenerative diseases. Some microRNAs (miRNAs) play critical roles in the development of many neurological diseases. This study aims to evaluate the clinical significance and biological function of miR-485-3p in the development and progression of PD. The expression of miR-485-3p in serum of PD patients was analyzed by quantitative real-time PCR (qRT-PCR). LPS-treated microglia BV2 cells were used to mimic neuroinflammation in the pathogenesis of PD. The levels of inflammatory cytokines, including IL-1β, IL-6 and TNF-α, were detected by enzyme-linked immunosorbent assay (ELISA). The diagnosis value of miR-485-3p was evaluated by plotting receiver operating characteristic (ROC) curves. A luciferase reporter assay was performed to demonstrate the interaction between miR-485-3p and FBXO45. The results showed that miR-485-3p was significantly up-regulated in serum of PD patients compared with that in both Alzheimer’s disease (AD) and healthy cases, and had diagnostic accuracy for PD screening. The activated microglia BV2 cells induced by LPS also had elevated miR-485-3p, and the knockdown of miR-485-3p inhibited the release of pro-inflammatory cytokines. FBXO protein 45 (FBXO45) served as a potential target of miR-485-3p, which was speculated to mediate the function of miR-485-3p. Our results suggest that the up-regulated expression of miR-485-3p in PD may be a novel diagnostic biomarker for PD. Reducing the expression level of miR-485-3p can inhibit the inflammatory responses of BV2 cells, which indicated that miR-485-3p, as a regulator of neuroinflammation, may have the potential as a therapeutic target in PD.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34279788</pmid><doi>10.1007/s12017-021-08676-w</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-4648-6256</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1535-1084 |
| ispartof | Neuromolecular medicine, 2022-06, Vol.24 (2), p.195-201 |
| issn | 1535-1084 1559-1174 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2553232720 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Alzheimer's disease Biomedical and Life Sciences Biomedicine Clinical significance Cytokines Cytokines - metabolism Enzyme-linked immunosorbent assay F-Box Proteins Humans IL-1β Inflammation Interleukin 6 Internal Medicine Lipopolysaccharides Lipopolysaccharides - pharmacology Microglia MicroRNAs miRNA Movement disorders Neurodegenerative diseases Neuroinflammatory Diseases Neurological diseases Neurology Neurosciences Original Paper Parkinson Disease - metabolism Parkinson's disease Patients Therapeutic targets Tumor necrosis factor-α |
| title | Diagnostic Performance of miR-485-3p in Patients with Parkinson’s Disease and its Relationship with Neuroinflammation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T23%3A23%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic%20Performance%20of%20miR-485-3p%20in%20Patients%20with%20Parkinson%E2%80%99s%20Disease%20and%20its%20Relationship%20with%20Neuroinflammation&rft.jtitle=Neuromolecular%20medicine&rft.au=Lin,%20Xia&rft.date=2022-06-01&rft.volume=24&rft.issue=2&rft.spage=195&rft.epage=201&rft.pages=195-201&rft.issn=1535-1084&rft.eissn=1559-1174&rft_id=info:doi/10.1007/s12017-021-08676-w&rft_dat=%3Cproquest_cross%3E2666132698%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2666132698&rft_id=info:pmid/34279788&rfr_iscdi=true |